Allogene Therapeutics Statistics Share Statistics Allogene Therapeutics has 218.73M
shares outstanding. The number of shares has increased by 4.6%
in one year.
Shares Outstanding 218.73M Shares Change (YoY) 4.6% Shares Change (QoQ) 0.67% Owned by Institutions (%) 91.53% Shares Floating 149.51M Failed to Deliver (FTD) Shares 62 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 25.93M, so 11.86% of the outstanding
shares have been sold short.
Short Interest 25.93M Short % of Shares Out 11.86% Short % of Float 14.35% Short Ratio (days to cover) 6.79
Valuation Ratios The PE ratio is -1.61 and the forward
PE ratio is -1.06.
Allogene Therapeutics's PEG ratio is
0.04.
PE Ratio -1.61 Forward PE -1.06 PS Ratio 18861.34 Forward PS 14714.8 PB Ratio 0.98 P/FCF Ratio -2.06 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Allogene Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.54,
with a Debt / Equity ratio of 0.21.
Current Ratio 8.54 Quick Ratio 8.54 Debt / Equity 0.21 Debt / EBITDA -0.37 Debt / FCF -0.45 Interest Coverage -1509.39
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $97.35 Profits Per Employee $-1.14M Employee Count 226 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 443K Effective Tax Rate -0.17%
Stock Price Statistics The stock price has increased by -56.36% in the
last 52 weeks. The beta is 0.36, so Allogene Therapeutics's
price volatility has been higher than the market average.
Beta 0.36 52-Week Price Change -56.36% 50-Day Moving Average 1.27 200-Day Moving Average 1.76 Relative Strength Index (RSI) 35.73 Average Volume (20 Days) 3,903,175
Income Statement In the last 12 months, Allogene Therapeutics had revenue of 22K
and earned -257.59M
in profits. Earnings per share was -1.32.
Revenue 22K Gross Profit -192.28M Operating Income -273.2M Net Income -257.59M EBITDA -243.33M EBIT -256.97M Earnings Per Share (EPS) -1.32
Full Income Statement Balance Sheet The company has 75.22M in cash and 90.76M in
debt, giving a net cash position of -15.54M.
Cash & Cash Equivalents 75.22M Total Debt 90.76M Net Cash -15.54M Retained Earnings -1.82B Total Assets 507.98M Working Capital 261.55M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -200.3M
and capital expenditures -694K, giving a free cash flow of -200.99M.
Operating Cash Flow -200.3M Capital Expenditures -694K Free Cash Flow -200.99M FCF Per Share -1.03
Full Cash Flow Statement Margins Gross margin is -873986.36%, with operating and profit margins of -1241813.64% and -1170863.64%.
Gross Margin -873986.36% Operating Margin -1241813.64% Pretax Margin -1168850% Profit Margin -1170863.64% EBITDA Margin -1106031.82% EBIT Margin -1241813.64% FCF Margin -913609.09%
